Last reviewed · How we verify
Meglumine antimoniate
At a glance
| Generic name | Meglumine antimoniate |
|---|---|
| Also known as | Glucantime, High dose, Low dose, Glucantime®, glucantime |
| Sponsor | University of Brasilia |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Randomised Clinical Trial for New Treatment Modalities for Cutaneous Leishmaniasis Caused by Leishmania Tropica, in Pakistan (PHASE3)
- Combination, Miltefosine Monotherapy for Cutaneous Leishmaniasis in New World (PHASE3)
- Arnica Tincture Fot the Treatment of Cutaneous Leishmaniasis II. (PHASE3)
- Treatment of Mucosal Bolivian Leishmaniasis (PHASE3)
- The Association of Miltefosine and Pentoxifylline to Treat Mucosal and Cutaneous Leishmaniasis: A Clinical Trial in Brazil (PHASE2)
- Tofacitinib Associated With Meglumine Antimoniate in Cutaneous Leishmaniasis (PHASE2, PHASE3)
- Topical Sm29 in Combination With Meglumine Antimoniate in the Treatment of Cutaneous Leishmaniasis. (PHASE1, PHASE2)
- Study of Cases of Cutaneous Leishmaniasis Treated With Miltefosine in French Guiana, Retrospective Study
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Meglumine antimoniate CI brief — competitive landscape report
- Meglumine antimoniate updates RSS · CI watch RSS
- University of Brasilia portfolio CI